繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-6

MB-6

Indication
Acting as Adjuvant for metastatic colorectal cancer
Product Advantages
reducing chemo-associated toxicity and enhancing efficacy of chemotherapy
Status
Phase III clinical trial is in progress
Competitive Edge
Oral capsule botanical drug, high safety, not much similar drugs currently on the market or under development
Potential Market
The analysis by GBI Research points out that the market value of colorectal cancer treatment will increase from 8.3 billion U.S. dollars in 2013 to 9.4 billion U.S. dollars in 2020
  • A series of preclinical studies had demonstrated that MB-6 reduced the incidence of colonic polyps and formation of tumor, prolonged survival rate as compared to chemotherapy alone when MB-6 was given together with 5-FU in colorectal cancer bearing mice.
  • MB-6 obtained USFDA and Taiwan Ministry of Health and Welfare (MOHW) phase II IND approval. In the Phase II clinical trials of patients with colorectal cancer in Taiwan, the combination of MB-6 and FOLFOX-4 standard treatment significantly prolonged progression-free survival (PFS) and overall survival, improved chemotherapeutic compliance, and improved FOLFOX-4-induced Neutropenia and reduce the dose of granulocyte colony stimulating factor (G-CSF) used

Phase II clinical trial


体彩p5中奖新闻 上海十一选五走势一定牛 中国福利彩票客户端 新快赢481开奖视频 山西快乐十分走势图电子版 股票配资平台正规 在线炒股配资仟推荐卓信宝 内蒙古十一选我五走势图 舟山飞鱼开奖号码 天津时时彩的官网开奖 上海股票配资哪家好